Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc (FRLN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
frln · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Freeline Therapeutics Holdings plc (FRLN) measures how much investors pay for each dollar of the company's trailing earnings. FRLN's current PE ratio of N/A is calculated by dividing its stock price of $6.49 by its TTM earnings per share of -$22.52.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2018 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Freeline Therapeutics Holdings plcYou FRLN | $28M | N/A | — | -$22.52 |
 Allakos Inc. ALLK | $30M | N/A | — | -$1.30 |
 Angion Biomedica Corp. ANGN | $30M | N/A | — | -$2.58 |
 AnPac Bio-Medical Science Co., Ltd. ANPC | $27M | N/A | — | -$54.18 |
 Elevation Oncology, Inc. ELEV | $22M | N/A | — | -$0.78 |
 Liminal BioSciences Inc. LMNL | $28M | N/A | — | -$341.80 |
 LakeShore Biopharma Co., Ltd LSB | $26M | N/A | — | -$0.94 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-22.52 | — | |
2021-12-31 FY2021 | — | $-58.98 | — | |
2020-12-31 FY2020 | — | $-102.09 | — | |
2019-12-31 FY2019 | — | $-127.39 | — | |
2018-12-31 FY2018 | — | $-78.65 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Freeline Therapeutics Holdings plc (FRLN) measures how much investors pay for each dollar of the company's trailing earnings. FRLN's current PE ratio of N/A is calculated by dividing its stock price of $6.49 by its TTM earnings per share of -$22.52.
Frequently asked questions
FRLN pe ratio · 6 questionsFRLN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $6.49 and TTM EPS of -$22.52. Data sourced from Financial Modeling Prep via FRLN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Freeline Therapeutics Holdings plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09